Login / Signup

Preclinical evaluation and phase 1 study of the PI3Kα/δ inhibitor TQ-B3525 in Chinese patients with advanced cancers.

Zhi-Ming LiXiang LiSu LiRong TaoXin TianFan FengWenqi JiangHuaqing Wang
Published in: Cancer (2024)
TQ-B3525 exhibited rapid absorption and a nearly proportional increase in exposure. Acceptable safety and promising efficacy support further investigation of TQ-B3525 (20 mg once daily) for R/R lymphoma.
Keyphrases
  • diffuse large b cell lymphoma
  • open label
  • cell therapy
  • stem cells
  • loop mediated isothermal amplification
  • double blind